GCM2 and breast carcinoma: To further evaluate whether the combined detection of circulating methylated GCM2 and TMEM240 could be used to monitor for recurrence or progressive disease in breast cancer patients according to the defined cutoff values, we validated the system with the data from 120 breast cancer patients from the USA and 205 patients from Taiwan.